ANH petitions FDA to restore homeopathic safe harbor

Alliance for Natural Health USA and Meditrend Inc. are asking FDA to reinstate a long-running policy that let compliant homeopathic medicines stay on the market without new drug approval, while the agency reopens the issue through formal rulemaking. The petition argues FDA’s current enforcement approach creates uncertainty, threatens access, and overreaches beyond products with documented safety problems.

Why it matters: - The petition seeks to preserve market access for homeopathic medicines that meet established labeling and quality standards. - ANH-USA says FDA’s current approach leaves manufacturers, retailers, practitioners and consumers without clear rules on what can be sold without enforcement risk. - The dispute could affect how FDA polices an entire category of products, not just individual bad actors.

What happened: - Alliance for Natural Health USA and Meditrend Inc. filed a Citizen Petition asking FDA to restore its former homeopathic safe harbor. - The filing asks FDA to stop using the agency’s December 2022 homeopathic drug guidance until formal public rulemaking is completed. - The petition was announced Oct. 1, 2026. - ANH-USA says FDA withdrew Compliance Policy Guide 400.400 in 2019 after 31 years in place. - FDA later finalized a risk-based enforcement guidance in December 2022.

The details: - The petition asks FDA to take four steps pending notice-and-comment rulemaking. - FDA should revoke the 2019 withdrawal of Compliance Policy Guide 400.400. - FDA should reinstate CPG 400.400 and its conditions for marketing homeopathic medicines. - FDA should cease implementation of the December 2022 enforcement framework. - FDA should begin rulemaking to define which homeopathic products may be sold in the U.S. without enforcement action. - The filing argues FDA failed to account for decades of reliance on CPG 400.400. - The petition also says FDA did not use the notice-and-comment process before adopting a policy with major industry impact. - ANH-USA and Meditrend argue their concern is not with enforcement against adulteration or misbranding, but with removing a clear framework for compliant products. - The petition’s scientific exhibit reviews 2,068 adverse event reports tied to homeopathic or purportedly homeopathic products. - The exhibit concludes FDA’s adverse event data do not justify treating properly manufactured, HPUS-compliant, correctly labeled homeopathic medicines as a broad public health threat. - The exhibit says FDA relied on isolated examples involving improperly manufactured, mislabeled, contaminated, pharmacologically dosed or non-compliant products. - The petition says those products were never entitled to the protections of CPG 400.400. - The filing argues enforcement should target specific bad actors or risky products. - In a sworn declaration, Meditrend President Seneca Savage says the policy shift hurt investor support, ingredient sourcing and manufacturing. - The petition proposes a “traffic-light” enforcement model. - Green products meeting defined homeopathic, labeling, manufacturing and low-risk criteria would get lowest enforcement priority. - Amber products with unresolved concerns would face additional scrutiny. - Red products with clear risks, including adulteration, contamination, misbranding, pharmacologically active exposure or causally supported serious adverse events, would be prioritized for enforcement. - The petition asks FDA to preserve its authority to act against adulteration, misbranding and genuine safety problems. - ANH-USA says the current uncertainty threatens consumer access to long-standing homeopathic products. - The petition is accompanied by a call for a transparent public process to define lawful homeopathic drug marketing. - ANH-USA is a 501(c)(4) nonprofit advocacy organization founded in 1992. - The organization says it defends access to natural and preventive healthcare and supports science-informed policy. - More information is available in ANH-USA's announcement.

Between the lines: - The petition frames the issue as a procedural and regulatory fairness dispute, not a demand for weaker safety standards. - The group is trying to separate compliant homeopathic products from higher-risk or non-compliant products. - The reference to the “MAHA agenda” signals an effort to align the petition with the current administration’s health-policy priorities. - The legal argument centers on reliance interests and the need for rulemaking before ending a long-standing policy.

What's next: - FDA could respond to the citizen petition, reopen the policy question or leave the current framework in place. - Any durable change would likely require formal rulemaking and public comment. - Until then, manufacturers of homeopathic products remain under a more uncertain enforcement regime.

The bottom line: - ANH-USA is pushing FDA to replace a broad enforcement shift with a clearer, tiered system that protects compliant homeopathic products while targeting genuinely risky ones.